Schauenstein E, Lahousen M, Weblacher M, Steinschifter W, Estelberger W, Schauenstein K
Department of Biochemistry, University of Graz, Graz, Austria.
Cancer. 1996 Aug 1;78(3):511-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<511::AID-CNCR19>3.0.CO;2-1.
Malignant diseases of various tissue origin have previously been found to be associated with a characteristic shift in the serum pattern of IgG subclasses, i.e., a highly significant reduction of the percent of IgG1 and an increase of the percentage of IgG2 relative to the total IgG. In the present study we examined the diagnostic performance of this indirect tumor marker in patients with carcinomas of various sites within the female reproductive tract.
Using quantitative affinity chromatography, the percents of IgG1 and IgG2 in the total IgG were determined for 207 patients with carcinoma of the ovary, cervix, or corpus uteri, prior to any treatment. The data were compared with those of 135 age matched healthy females and 52 patients with benign gynecologic diseases.
It was found that (1) mean values for the percents of IgG1 and IgG2 of all of the cancer patients differed significantly from those of the patients with benign disease and healthy controls; (2) no differences were noted between carcinomas of the ovary, corpus or cervix uteri; (3) early stages of carcinoma exhibited the effect to the same extent as late stages; (4) the specificity of the percent of IgG1 to discriminate between controls and cancer patients ranged between 90 and 100%, regardless of localization and stage of tumor; and (5) whereas with ovarian cancer CA 125 showed a slightly greater sensitivity, the percent of IgG1 was by far more sensitive than the conventional markers CA 125, TPA, CEA, Ferritin, and SCC to diagnose carcinoma of the cervix and corpus uteri, notably at early stages. Combined analysis of the percent of IgG1 and CA 125 and/or TPA led to an increase in sensitivity with tumors of all three sites.
Thus, the determination of the percent of IgG1 by itself and/or in combination with conventional markers may provide relevant information regarding the noninvasive detection of early stages of gynecologic carcinoma.
先前已发现各种组织来源的恶性疾病与血清IgG亚类模式的特征性变化相关，即相对于总IgG，IgG1百分比显著降低，IgG2百分比升高。在本研究中，我们检测了这种间接肿瘤标志物在女性生殖道不同部位癌患者中的诊断性能。
采用定量亲和层析法，对207例卵巢癌、宫颈癌或子宫体癌患者在任何治疗前测定总IgG中IgG1和IgG2的百分比。将数据与135名年龄匹配的健康女性和52例良性妇科疾病患者的数据进行比较。
发现（1）所有癌症患者的IgG1和IgG2百分比平均值与良性疾病患者和健康对照者有显著差异；（2）卵巢癌、子宫体癌或宫颈癌之间未发现差异；（3）癌的早期和晚期表现出相同程度的效应；（4）无论肿瘤的定位和分期如何，IgG1百分比区分对照者和癌症患者的特异性在90%至100%之间；（5）虽然CA 125对卵巢癌显示出稍高的敏感性，但IgG1百分比对诊断子宫颈癌和子宫体癌远比传统标志物CA 125、TPA、CEA、铁蛋白和SCC敏感，尤其是在早期。IgG1百分比与CA 125和/或TPA的联合分析导致所有三个部位肿瘤的敏感性增加。
因此，单独测定IgG1百分比和/或与传统标志物联合测定可能为妇科癌早期的无创检测提供相关信息。
